BACKGROUND: Based partially on encouraging findings from preclinical models, interest has grown in therapeutic inhibition of NF-kappaB to limit inflammatory injury during sepsis. However, NF-kappaB also regulates protective responses, and predicting the net survival effects of such inhibition may be difficult. OBJECTIVES: To highlight the caution necessary with this therapeutic approach, we review our investigations in a mouse sepsis model with parthenolide and ethyl pyruvate, two NF-kappaB inhibitors proposed for clinical study. RESULTS: Consistent with published studies, parthenolide decreased NF-kappaB binding activity and inflammatory cytokine release from lipopolysaccharide (LPS) stimulated RAW 264.7 cells in vitro. In LPS-challenged mice (C57BL/6J), however, while both agents decreased lung and kidney NF-kappaB binding activity and plasma cytokines early (1-3 h), these measures were increased later (6-12 h) in patterns differing significantly over time. Furthermore, despite studying several doses of parthenolide (0.25-4.0 mg/kg) and ethyl pyruvate (0.1-100 mg/kg), each produced small but consistent decreases in survival which overall were significant (p < or = 0.04 for each agent). CONCLUSION: While NF-kappaB inhibitors hold promise for inflammatory conditions such as sepsis, caution is necessary. Clear understanding of the net effects of NF-kappaB inhibitors on outcome will be necessary before such agents are used clinically.
BACKGROUND: Based partially on encouraging findings from preclinical models, interest has grown in therapeutic inhibition of NF-kappaB to limit inflammatory injury during sepsis. However, NF-kappaB also regulates protective responses, and predicting the net survival effects of such inhibition may be difficult. OBJECTIVES: To highlight the caution necessary with this therapeutic approach, we review our investigations in a mousesepsis model with parthenolide and ethyl pyruvate, two NF-kappaB inhibitors proposed for clinical study. RESULTS: Consistent with published studies, parthenolide decreased NF-kappaB binding activity and inflammatory cytokine release from lipopolysaccharide (LPS) stimulated RAW 264.7 cells in vitro. In LPS-challenged mice (C57BL/6J), however, while both agents decreased lung and kidney NF-kappaB binding activity and plasma cytokines early (1-3 h), these measures were increased later (6-12 h) in patterns differing significantly over time. Furthermore, despite studying several doses of parthenolide (0.25-4.0 mg/kg) and ethyl pyruvate (0.1-100 mg/kg), each produced small but consistent decreases in survival which overall were significant (p < or = 0.04 for each agent). CONCLUSION: While NF-kappaB inhibitors hold promise for inflammatory conditions such as sepsis, caution is necessary. Clear understanding of the net effects of NF-kappaB inhibitors on outcome will be necessary before such agents are used clinically.
Authors: Mihaela Gadjeva; Michal F Tomczak; Ming Zhang; Yan Yan Wang; Karen Dull; Arlin B Rogers; Susan E Erdman; James G Fox; Michael Carroll; Bruce H Horwitz Journal: J Immunol Date: 2004-11-01 Impact factor: 5.422
Authors: Runkuan Yang; Takashi Uchiyama; Sean M Alber; Xiaonan Han; Simon K Watkins; Russell L Delude; Mitchell P Fink Journal: Crit Care Med Date: 2004-07 Impact factor: 7.598
Authors: Peter C Minneci; Katherine J Deans; Steven M Banks; Peter Q Eichacker; Charles Natanson Journal: Ann Intern Med Date: 2004-07-06 Impact factor: 25.391
Authors: Angel López; Jose Angel Lorente; Jay Steingrub; Jan Bakker; Angela McLuckie; Sheila Willatts; Michael Brockway; Antonio Anzueto; Laurent Holzapfel; Desmond Breen; Michael S Silverman; Jukka Takala; Jill Donaldson; Carl Arneson; Geraldine Grove; Steven Grossman; Robert Grover Journal: Crit Care Med Date: 2004-01 Impact factor: 7.598
Authors: Gagan S Thangjam; Charalampos Birmpas; Nektarios Barabutis; Betsy W Gregory; Mary Ann Clemens; Joseph R Newton; David Fulton; John D Catravas Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-04-01 Impact factor: 5.464
Authors: Jessica A Dominguez; Alexandr J Samocha; Zhe Liang; Eileen M Burd; Alton B Farris; Craig M Coopersmith Journal: Crit Care Med Date: 2013-10 Impact factor: 7.598
Authors: Joachim Bischof; Johann Leban; Mirko Zaja; Arnhild Grothey; Barbara Radunsky; Olaf Othersen; Stefan Strobl; Daniel Vitt; Uwe Knippschild Journal: Amino Acids Date: 2012-02-14 Impact factor: 3.520
Authors: Nuria E Cabrera-Benitez; Eduardo Pérez-Roth; Milena Casula; Angela Ramos-Nuez; Carla Ríos-Luci; Carlos Rodríguez-Gallego; Ithaisa Sologuren; Virginija Jakubkiene; Arthur S Slutsky; José M Padrón; Jesús Villar Journal: PLoS One Date: 2012-11-08 Impact factor: 3.240